| Foot Doctor Llc | |
|
808 Fremont St, Ashton, ID 83420-1210 | |
| (307) 359-9566 | |
| Not Available |
| Full Name | Foot Doctor Llc |
|---|---|
| Type | Facility |
| Speciality | Podiatrist - Foot & Ankle Surgery |
| Location | 808 Fremont St, Ashton, Idaho |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700665775 | NPI | - | NPPES |
| Provider Name | Travis G Marshall |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1992020432 PECOS PAC ID: 6901058262 Enrollment ID: I20231023000394 |
News Archive
In conjunction with the Charing Cross International Symposium (CX34), which concludes today in London, Minneapolis-based Medtronic, Inc. announced its plans for the imminent start of the IN.PACT Global SFA clinical study, an international research program to evaluate the treatment of peripheral artery disease using the company's IN.PACT Admiral drug-eluting balloon.
Australian biopharmaceutical company Immuron Limited has today announced a significant milestone in its Phase 2 clinical trial for non-alcoholic steatohepatitis (NASH) with the recruitment of its first two patients at Duke University in the United States. It is expected that further recruitment at Duke and other sites in the US and Australia will follow in early course.
A comprehensive analysis of the genomes of nearly 500 papillary thyroid carcinomas (PTC) – the most common form of thyroid cancer – has provided new insights into the roles of frequently mutated cancer genes and other genomic alterations that drive disease development.
78 TNBC biopsies from patients with different responses to chemotherapy were analysed for API-5 expression before any treatment.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Foot Doctor Llc Po Box 804, Ashton, ID 83420-0804 Ph: (307) 359-9566 | Foot Doctor Llc 808 Fremont St, Ashton, ID 83420-1210 Ph: (307) 359-9566 |
News Archive
In conjunction with the Charing Cross International Symposium (CX34), which concludes today in London, Minneapolis-based Medtronic, Inc. announced its plans for the imminent start of the IN.PACT Global SFA clinical study, an international research program to evaluate the treatment of peripheral artery disease using the company's IN.PACT Admiral drug-eluting balloon.
Australian biopharmaceutical company Immuron Limited has today announced a significant milestone in its Phase 2 clinical trial for non-alcoholic steatohepatitis (NASH) with the recruitment of its first two patients at Duke University in the United States. It is expected that further recruitment at Duke and other sites in the US and Australia will follow in early course.
A comprehensive analysis of the genomes of nearly 500 papillary thyroid carcinomas (PTC) – the most common form of thyroid cancer – has provided new insights into the roles of frequently mutated cancer genes and other genomic alterations that drive disease development.
78 TNBC biopsies from patients with different responses to chemotherapy were analysed for API-5 expression before any treatment.
› Verified 7 days ago
Dr. Travis G Marshall, D.P.M Podiatrist Medicare: Medicare Enrolled Practice Location: 808 Fremont St, Ashton, ID 83420 Phone: 307-359-9566 |